{"created":"2023-05-15T16:49:25.483849+00:00","id":26875,"links":{},"metadata":{"_buckets":{"deposit":"9cab6ee4-7cb8-4151-82d6-11fbd9d544dc"},"_deposit":{"created_by":6,"id":"26875","owners":[6],"pid":{"revision_id":0,"type":"depid","value":"26875"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00026875","sets":["8:9"]},"author_link":["119355","119345","119347","119348","119352","119353","119350","119349","119356","119354","119346","119351"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021-08-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"8","bibliographicPageEnd":"1087","bibliographicPageStart":"1081","bibliographicVolumeNumber":"44","bibliographic_titles":[{"bibliographic_title":"Biological and Pharmaceutical Bulletin"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Naldemedine (NAL), a peripherally acting μ-opioid receptor antagonist, is effective for opioid-induced constipation (OIC). However, diarrhea is the most common adverse event. We investigated the incidence of NAL-induced diarrhea in patients who started NAL at Nagasaki University Hospital between June 2017 and March 2019. Predictors of NAL-induced diarrhea were analyzed using a multivariate logistic regression model. Two hundred and forty-two patients were included in the present study, and NAL-induced diarrhea was observed in 17.8% (43 patients). The results of multiple logistic regression analyses identified the administration of opioid analgesics for 8 d or longer before the initiation of NAL (odds ratio (OR): 2.20, 95% confidence interval (95% CI): 1.04–4.64, p = 0.039), the combination of a laxative (OR: 2.22, 95%CI: 1.03–4.81, p = 0.042), and the combination of CYP3A4 inhibitors (strong/moderate) (OR: 2.80, 95%CI: 1.02–7.67, p = 0.045) as risk factors. Therefore, the development of diarrhea needs to be considered in patients with these risk factors. Furthermore, diarrhea may be controlled by the initiation of NAL within 7 d of opioid analgesics and, where possible, the discontinuation of or change in the combination of moderate or strong CYP3A4 inhibitors.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Biological and Pharmaceutical Bulletin, 44(8), pp. 1081-1087; 2021","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"日本薬学会 "}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1248/bpb.b21-00209","subitem_relation_type_select":"DOI"}}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© 2021 The Pharmaceutical Society of Japan"}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0918-6158","subitem_source_identifier_type":"ISSN"}]},"item_2_source_id_8":{"attribute_name":"EISSN","attribute_value_mlt":[{"subitem_source_identifier":"1347-5215","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Hashizume, Junya"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Shiojiri, Kyohei"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ryu, Emi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kawauchi, Yuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hasegawa, Kyoko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ezaki, Nozomi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yamashita, Haruna"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ishii, Koji"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Harasawa, Hitomi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nakamura, Tadahiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Sasaki, Hitoshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kodama, Yukinobu"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-11-19"}],"displaytype":"detail","filename":"BPBul44_1081.pdf","filesize":[{"value":"372.1 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"BPBul44_1081.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/26875/files/BPBul44_1081.pdf"},"version_id":"5eece89f-14e2-4a26-811c-e339061434c6"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"naldemedine","subitem_subject_scheme":"Other"},{"subitem_subject":"diarrhea","subitem_subject_scheme":"Other"},{"subitem_subject":"predictive factor","subitem_subject_scheme":"Other"},{"subitem_subject":"opioid analgesic","subitem_subject_scheme":"Other"},{"subitem_subject":"laxative","subitem_subject_scheme":"Other"},{"subitem_subject":"CYP3A4 inhibitor","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Analysis of Predictive Factors for Diarrhea after the Administration of Naldemedine","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Analysis of Predictive Factors for Diarrhea after the Administration of Naldemedine"}]},"item_type_id":"2","owner":"6","path":["9"],"pubdate":{"attribute_name":"公開日","attribute_value":"2021-11-19"},"publish_date":"2021-11-19","publish_status":"0","recid":"26875","relation_version_is_last":true,"title":["Analysis of Predictive Factors for Diarrhea after the Administration of Naldemedine"],"weko_creator_id":"6","weko_shared_id":-1},"updated":"2023-05-15T20:08:09.121574+00:00"}